Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05240898 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
- 15
- Study locations
NCT05240898 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Hoffmann-La Roche. The registered enrollment target is 116 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (41% lower). The trial reports 15 study locations across 12 states.
The verdict
NCT05240898, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Olaparib
- DRUG RO7623066
Study Locations (15)
Texas
- Mary Crowley Medical Research Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Ohio
- Cleveland Clinic, - Cleveland
- The Ohio State University Comprehensive Cancer Center - Columbus
California
- University of California Irvine Medical Center - Orange
Connecticut
- Yale School of Medicine - New Haven
Maine
- Barbara Ann Karmanos Cancer Institute - Detroit
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- South Texas Accelerated Research Therapeutics (START) - Midwest Location - Grand Rapids
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2021-08-26 |
| Est. Completion | 2025-11-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05240898
The ClinicalTrials.gov registry entry for NCT05240898 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (41% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT05240898 reports 15 study locations spanning 12 distinct geographic areas - top geographies include Texas, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT05240898 about?
NCT05240898 is a clinical study titled "A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors". This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.
What is the current status of trial NCT05240898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2021-08-26. Estimated completion is 2025-11-26.
What conditions does trial NCT05240898 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT05240898?
The interventions under investigation include: Carboplatin (DRUG), Olaparib (DRUG), RO7623066 (DRUG).
Who is sponsoring clinical trial NCT05240898?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05240898 being conducted?
This trial has 15 study locations across California, Connecticut, Maine, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.